M K Proteins Ltd. exhibits mixed financial performance. While the compounded sales growth shows a 10-year average of 8% and a recent TTM of 9%, the 3-year growth is only 2%, indicating a slowdown. The compounded profit growth presents a similar picture, with a strong 10-year growth of 26% and a 5-year growth of 36%, but a concerning -6% over the last 3 years and a -25% TTM. Quarterly results show fluctuating sales and profits, with YOY Sales Growth varying significantly. The OPM% also fluctuates, from 9.70% in Mar 2024 to 3.39% in Mar 2025. This inconsistent performance raises concerns about the sustainability of growth.

The capital efficiency of M K Proteins Ltd. shows mixed signals. The Return on Capital Employed (ROCE) has fluctuated over the years, peaking at 29% in 2021 but declining to 13% in 2025. Similarly, the Return on Equity (ROE) has decreased from 21% over 10 years to 13% in the last year. The cash conversion cycle has been lengthening, reaching 142 days in March 2025, indicating potential inefficiencies in working capital management. The ROCE % decreased from 10% during 2014-2016 to 13% in Mar 2025. This trend suggests that the company's efficiency in utilizing capital to generate returns is declining.

M K Proteins Ltd.'s financial health presents a mixed picture. Borrowings have fluctuated, with a recent increase to ₹39 Cr in Mar 2025 after a decrease in Mar 2024. The debt-to-equity ratio, while not explicitly provided, can be inferred to have increased with the rise in borrowings against a relatively stable equity base. The company has not been paying dividends, indicated by a consistent 0% dividend payout. The interest coverage ratio can be inferred from the operating profit and interest expenses, showing sufficient coverage, but this needs continuous monitoring. The borrowings increased from 28 Cr (2014) to 39 Cr (2025).

The shareholding structure of M K Proteins Ltd. shows a strong positive signal with consistently high promoter holding. Promoters hold approximately 74.82% to 74.83% of the shares from September 2021 to March 2025, indicating strong confidence in the company's prospects. FII holding is negligible, and the public holding constitutes the remaining 25.17% to 25.18%. The number of shareholders has significantly increased over time, from 42 in September 2021 to 67,754 in March 2025, showing growing public interest. This high promoter holding is a strong indicator of management's commitment and alignment with shareholder interests.

M K Proteins Ltd. shows segment performance volatility as evidenced by the fluctuating quarterly sales and profit growth. The YOY Sales Growth % varies significantly, from -25% in Jun 2024 to 147% in Sep 2024, and 58% in Mar 2025. Similarly, the YOY Profit Growth % fluctuates, from -0% in Jun 2024 to 324% in Sep 2024, and -52% in Mar 2025. These fluctuations suggest instability in the company's operational performance.

Based on the provided data for M K Proteins Ltd., there is no explicit indication of significant foreign exchange exposure. The company's operations appear to be primarily domestic, with borrowings that carry some level of interest rate risk. The interest expenses are relatively stable.

There is no specific data available to evaluate contingent liabilities for M K Proteins Ltd. The balance sheet and profit/loss statements do not provide explicit details regarding potential legal claims, guarantees, or other off-balance-sheet obligations that could materially impact the company's financial position. The absence of this information makes it difficult to assess the potential risks associated with unforeseen liabilities.